Cancer Network

Cancer Network

Cancer Network, along with the peer-reviewed journal ONCOLOGY, offers healthcare professionals valuable insights and expert opinions on topics related to cancer. This includes information on screening, early detection, diagnosis, treatment options, and prevention strategies for various types of cancer.

International
English
Journal, Online/Digital

Outlet metrics

Domain Authority
63
Ranking

Global

#312172

United States

#144835

Health/Health

#2863

Traffic sources
Monthly visitors

Articles

  • 4 days ago | cancernetwork.com | Tim Cortese

    Retreatment with [177Lu]Lu-PSMA-617 (Pluvicto) showed that it may offer clinical benefit and was well tolerated in a small cohort of patients with metastatic castration-resistant prostate cancer (CRPC) who had sustained prostate-specific membrane antigen (PSMA) expression, according to results from a retrospective single-center study shared at the 2025 Society of Nuclear Medicine and Molecular Imaging Annual Meeting.1 Previously, in March 2022, [177Lu]Lu-PSMA-617 was approved for adult...

  • 1 week ago | cancernetwork.com | Tim Cortese

    Adjuvant aspirin did not reduce the rate of recurrence nor improve survival outcomes for patients with colorectal cancer (CRC) liver metastases and cannot be recommended as an adjuvant treatment, according to results from the randomized phase 3 ASAC trial (NCT03326791).1 These findings were shared at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

  • 1 week ago | cancernetwork.com | Tim Cortese

    Mezigdomide (Mezi) plus dexamethasone and bortezomib (Velcade; MeziVd) or carfilzomib (Kyprolis; MeziKd) demonstrated promising efficacy and a manageable safety profile across all dose levels in patients with relapsed or refractory multiple myeloma, as shown in the results of the phase 1/2 CC-92480-MM-002 trial (NCT03989414) shared at the European Hematology Association 2025 Congress.

  • 1 week ago | cancernetwork.com | Tim Cortese

    First-line systemic therapy plus radiation therapy for oligoprogressive lesions (m-FLST + RT) may offer clinical benefit without the need for second-line systemic therapy with or without radiation therapy (s-SLST + RT) in the treatment of patients with oligoprogressive hepatocellular carcinoma (HCC), according to results from a study published in the International Journal of Radiation Oncology, Biology, and Physics.

  • 1 week ago | cancernetwork.com | Tim Cortese

    The FDA has approved tafasitamab-cxix (Monjuvi) in combination with lenalidomide (Revlimid) and rituximab (Rituxan) as a treatment for patients with relapsed or refractory follicular lymphoma, according to a release from the agency.1Supporting results from the double-blind, placebo-controlled phase 3 inMIND trial (NCT04680052) compared the approved combination vs placebo with lenalidomide and rituximab.

Cancer Network journalists